Esperion Therapeutics Stock Forum

$Esperion Therapeutics(ESPR.US)$ seems like a good time To jump in

$Esperion Therapeutics(ESPR.US)$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...

$Esperion Therapeutics(ESPR.US)$ Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
– NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) –
– CLEAR Outcomes Sets New Standards for Diversity and Inclusion ...

$Esperion Therapeutics(ESPR.US)$ Not worried unless it drops below 2.63? If that happens 2.12 could be possible? But for now after the uptrend its been on, im just looking at is as a bit of a pullback! Especially with the amount of shares sold short just today! Lit exchange alone over 1 million! Not counting the ones routed to DP! JMO

$Esperion Therapeutics(ESPR.US)$ game over

$Esperion Therapeutics(ESPR.US)$
HOT NEWS ON OBESITY STUDY
Esperion (Nasdaq: ESPR) presented positive results from the CLEAR Outcomes trial at the 2024 American College of Cardiology’s Annual Scientific Sessions. Patients with obesity on NEXLETOL had a 23% lower risk of MACE-4 compared to placebo. The trial highlighted benefits in women and Hispanic/Latinx patients, emphasizing the importance of early LDL-C lowering for reducing cardiovascular events.

$Esperion Therapeutics(ESPR.US)$ or are we expecting some surprise good news.

$Esperion Therapeutics(ESPR.US)$ $25 is my PT